Press
Press releases
All StemInov corporate announcements, newest first.
Septembre 24th, 2025
StemInov raises €10.6 million to accelerate its industrial and clinical development
This financing will enable StemInov to scale up the industrialization of its stem cell-based technology and prepare the clinical entry of its breakthrough therapy for severe pneumonia – a life-threatening condition with no specific treatment available today.
June 26th, 2024
StemInov and the Nancy Regional University Hospital have received €5.2 million in funding as part of the France 2030 “Innovations in Biotherapies and Bioproduction” call for projects to develop the first GMP clinical platform for mesenchymal stem cells derived from the umbilical cord.
Media contact
For all press and media enquiries, interview requests and visual assets.
Nom du contact presse à définir avec StemInov
Fonction à définir avec StemInov
StemInov SAS · 2 avenue de la Forêt de Haye · 54520 Vandœuvre-lès-Nancy
About StemInov
StemInov is a French biotechnology company founded in 2019 as a spin-off of the Nancy Regional University Hospital (CHRU de Nancy) and the University of Lorraine. The company develops a proprietary 3D bioproduction platform for mesenchymal stem cells, designed to deliver off-the-shelf allogeneic therapies at clinical scale.
Its lead candidate, WhartSep®, is a Wharton’s jelly mesenchymal stem cell therapy targeting severe community-acquired pneumonia associated with ARDS and sepsis. StemInov is based in Vandœuvre-lès-Nancy, France.
Partners
R&D
Support
Labels
